20/20 GeneSystems, Inc. - Company Profile - Crowdonomics
top of page
Image-empty-state_edited.jpg

20/20 GeneSystems, Inc.

Early Cancer Detection. Powered by AI.
Favorite-Icon-p-1600.png
Favorite-Icon-p-1600_filled.png
Login to favorite a company
Most Recent Valuation:

$58,400,000.00

Legal Name:
Founded:
State of HQ:

20/20 GeneSystems, Inc.

9/28/2000

MD

Company Description

​

Employees:

Funding Summary

Number of funding rounds
6
Total amount raised
$8,343,755
Round name
End date
Raised
Status
Type
Investment minimum
Valuation
Valuation Cap
Price per share
20/20 GeneSystems, Inc. Convertible Note 2
03/21/2023
$232,186.66
closed
Convertible Note
$500
$58,400,000
Round 3 Reg A? https://www.sec.gov/cgi-bin/browse-edgar?CIK=1139685
06/16/2021
$2,909,129.00
closed
Common Stock
$502
$38,500,000
4.4
10/30/2020
$3,791,881.00
closed
Preferred Stock
$502
$38,500,000
4.4
20/20 GeneSystems Reg A+ 3
05/16/2020
$1,410,558.00
closed
Preferred Stock
$502
4.4
20/20 GeneSystems Stock Reg A 2
closed
Preferred Stock
3.53
20/20 GeneSystems Stock 1
closed
Preferred Stock
3.26
Screen Shot 2020-07-15 at 12.01.28 PM.pn

See round history

Round history

Round name
Perk description
Perk level (dollars)
Perk level (days)
Loading...

Early Bird Perk history

Screen Shot 2020-07-15 at 12.01.28 PM.pn

View early bird perks, deal notes, company financials, and more

Company notes

Type
Round name
Date Added
Date Updated
Notes
Loading...

Financials (up to prior 4 years)

Revenue
COGS
Gross margin | (%)
Taxes
SG&A, other
Net income
Cash/Equivalents
Accounts Receiv
Other Assets
Assets
Short term debt
Long term debt
Equity/other liabilities

Gross margin, Other Assets, and Equity/other liabilities are derived from the financial statements of the company reported to the SEC. Assets = Liabilities + Equity, and no equity accounts nor accounts payable are reported to the SEC, hence the possibility for that amount to be either equity or a liability.

bottom of page